Nightingale Health Plc has received three new patent approvals from the Finnish Patent Authority. Nightingale Health announced on 23 May 2023 that it had received six patent approvals and with these three new patents the company's patent portfolio expands to self-collected finger-prick blood samples and more disease areas. The first of the newly received patents was granted for the company's proprietary technology's ability to determine with selected biomarkers analyzed from a dry blood sample, collected from a finger prick, whether an individual has a disease or condition or is at risk of developing a disease or condition.

The second patent was granted for the ability to determine whether an individual is at risk of developing an anxiety disorder. The third patent was granted for the ability to determine whether an individual is at risk of developing a connective tissue disease such as rheumatoid arthritis. The patents further increase the value of the company's intellectual property assets.

Nightingale Health has several other patent applications pending at the Finnish Patent Authority. The company is also in the process of expanding its patents internationally.